Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-932 in Depressive Episodes Associated With Bipolar I or II Disorder
NCT06605599Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ABBV-932 in bipolar I disorder and Bipolar II disorder (BP-II) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Total Score at 6 weeks. Started Oct 2024; status: completed.
02
Drugs
ABBV-932
03
Conditions
bipolar I disorderBipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT06605599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06605599.